Research programme: infectious disease vaccine - Codagenix

Drug Profile

Research programme: infectious disease vaccine - Codagenix

Alternative Names: CDX EC; CDX-DENV-14; CDX-RSV-A; CDX-ZKV

Latest Information Update: 28 Nov 2016

Price : $50

At a glance

  • Originator Codagenix
  • Class Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Dengue; Escherichia coli infections; Influenza virus infections; Respiratory syncytial virus infections; Zika virus infection

Most Recent Events

  • 28 Nov 2016 Preclinical trials in Dengue in USA (Parenteral) before November 2016
  • 28 Nov 2016 Preclinical trials in Escherichia coli infections in USA (Parenteral) before November 2016
  • 28 Nov 2016 Preclinical trials in Influenza virus infections in USA (Intranasal) before November 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top